Dr. Ash Tewari: “Tailored Prostate Cancer Treatment Offers New Hope for Patients”
Last fall, at the age of 49, Michael Zacharia was diagnosed with prostate cancer. A lot has changed in the way of treatment since his father learned of his cancer in 2002, however. Tewari and his team use this type of model, which include genomics, in treating prostate cancer. "Taking it to the molecular level or the genomic level, it helps us in understanding which kind of a targeted therapy will work in one patient versus the other patient—who will be a better candidate for radiation. This all can be deciphered based on analysis of DNA," said Ash Tewari, MBBS, MCh, Chair of Urology, Icahn School of Medicine at Mount Sinai and Chairman, Milton and Carroll Petrie Department of Urology at the Mount Sinai Hospital. Learn More
Immunotherapy After Bladder Cancer Surgery Shows Excellent Cancer-free Survival Rates
May 14, 2022 View All Press ReleasesMount Sinai Receives $1 Million Grant for Prostate Cancer Research
Dec 05, 2019 View All Press Releases